$ query --field benefits
PT-141 Benefits Reported in Research
The measured upside, the indication it was measured in, and the re-analyses that argue it is modest — all read straight off the trial record.
The short version
The documented PT-141 benefits come almost entirely from one place: the trials in premenopausal women with hypoactive sexual desire disorder (HSDD). In those studies, bremelanotide modestly but measurably increased sexual desire and reduced the distress that low desire caused [3]. The improvements held up over a year of as-needed use [4]. A brain-imaging study showed the compound actually changes how the brain processes sexual cues, which supports the idea that the benefit is real and central, not imagined [5]. Two honest caveats belong right next to those benefits. First, the size of the effect is debated: independent re-analyses argue the improvement, while statistically significant, is small in day-to-day terms. Second, benefits beyond that one approved group — PT-141 for women after menopause, or any benefit in men — are not established by approval, even where early data exist. This page sorts what the research actually measured, with no dose recommended and nothing sold.
PT-141 for women: the measured benefit
The strongest PT-141 benefits data come from the two RECONNECT Phase 3 trials, which enrolled 1,267 premenopausal women with HSDD. Bremelanotide 1.75 mg given under the skin as needed produced a statistically significant improvement in sexual desire — an integrated increase of +0.35 on the FSFI desire score (a validated questionnaire) — and reduced desire-related distress (an integrated change of -0.33 on a validated distress item), both versus placebo over 24 weeks (P<.001 for each) [3]. A 52-week open-label extension in 684 women found those desire improvements were sustained with no new safety signals [4]. A 2025 conference abstract reported additional positive signals on arousal and orgasm in premenopausal women, though abstracts are preliminary by nature [13]. Notably, the benefit appeared in female-rat work first: PT-141 selectively increased appetitive, solicitational (desire-driven) sexual behaviors without changing reflexive behaviors or motor activity — the first pharmacological agent reported to act this way on appetitive female sexual behavior [2].
How modest is the benefit, really
Stating the benefit honestly means stating its size. The RECONNECT endpoints — roughly a third of a point on the desire and distress scales — were statistically significant, but independent critical re-analyses have argued the effects on desire and distress are small and have questioned their clinical meaningfulness and the outcome measures used. An approval review summarized the same trial data, dosing, and adverse-event profile for clinicians [12], and a head-to-head conference analysis has begun comparing bremelanotide with other female-sexual-dysfunction therapies [14]. The fair reading: the benefit is real and reproducible across two large trials, and it is modest. Both facts are true at once.
What is not an approved benefit
The approval boundary is the most important context for any benefit claim. Bremelanotide is approved only for acquired, generalized HSDD in premenopausal women [7]. It is not approved for men, for postmenopausal women, or to enhance sexual performance, even though Phase 2 erectile-dysfunction data exist in men [1]. Early erectile-activity findings in men with erectile dysfunction were real but early-stage [1], and one 2008 erectile-dysfunction salvage study later received a 2023 Expression of Concern — a formal editorial notice that its integrity is in question — so its findings should be treated as disputed [1]. The takeaway is precise: a documented benefit in one population is not evidence of benefit in another, and approval has been granted for one group only. The reported and cited downsides are on the PT-141 effects page.